CD80 and hepatocellular carcinoma: Especially in HCC the former might contribute to the effect of ICI therapies targeting PD-L-1 and CTLA-4, since HCC tumour cells of early-relapsed disease demonstrated enhanced interaction of PD-L-1 and CTLA-4 with CD80/86 compared to primary HCC tumour cells (45).